GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Elanix Biotechnologies AG (FRA:ELN) » Definitions » Intrinsic Value: Projected FCF

Elanix Biotechnologies AG (FRA:ELN) Intrinsic Value: Projected FCF : €0.00 (As of May. 29, 2024)


View and export this data going back to . Start your Free Trial

What is Elanix Biotechnologies AG Intrinsic Value: Projected FCF?

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.

As of today (2024-05-29), Elanix Biotechnologies AG's Intrinsic Value: Projected FCF is €0.00. The stock price of Elanix Biotechnologies AG is €0.053. Therefore, Elanix Biotechnologies AG's Price-to-Intrinsic-Value-Projected-FCF of today is 0.0.

The historical rank and industry rank for Elanix Biotechnologies AG's Intrinsic Value: Projected FCF or its related term are showing as below:

FRA:ELN's Price-to-Projected-FCF is not ranked *
in the Drug Manufacturers industry.
Industry Median: 1.58
* Ranked among companies with meaningful Price-to-Projected-FCF only.

Elanix Biotechnologies AG Intrinsic Value: Projected FCF Historical Data

The historical data trend for Elanix Biotechnologies AG's Intrinsic Value: Projected FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Elanix Biotechnologies AG Intrinsic Value: Projected FCF Chart

Elanix Biotechnologies AG Annual Data
Trend Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18
Intrinsic Value: Projected FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 23.43 2.02 1.97 -1.06 -1.75

Elanix Biotechnologies AG Semi-Annual Data
Dec08 Dec09 Jun10 Dec10 Jun11 Dec11 Jun12 Dec12 Jun13 Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18
Intrinsic Value: Projected FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.97 - -1.06 - -1.75

Competitive Comparison of Elanix Biotechnologies AG's Intrinsic Value: Projected FCF

For the Drug Manufacturers - Specialty & Generic subindustry, Elanix Biotechnologies AG's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Elanix Biotechnologies AG's Price-to-Projected-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Elanix Biotechnologies AG's Price-to-Projected-FCF distribution charts can be found below:

* The bar in red indicates where Elanix Biotechnologies AG's Price-to-Projected-FCF falls into.



Elanix Biotechnologies AG Intrinsic Value: Projected FCF Calculation

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.

The details of how we calculate the intrinsic value of stocks are described in detail here.

This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + 0.8 * Total Stockholders Equity (most recent) ) / Shares Outstanding (Diluted Average)

In the case of negative Total Stockholders Equity, the following formula is used (see Explanation section below for the reason):

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + Total Stockholders Equity (most recent) / 0.8 ) / Shares Outstanding (Diluted Average)


Add all the Free Cash Flow together and divide 6 will get Elanix Biotechnologies AG's Free Cash Flow(6 year avg) = €-1.12.

Elanix Biotechnologies AG's Intrinsic Value: Projected FCF for today is calculated as

Intrinsic Value: Projected FCF=(Growth Multiple*Free Cash Flow (6 year avg)+Total Stockholders Equity (Dec18)/0.8)/Shares Outstanding (Diluted Average)
=(9.5203515959648*-1.1222857142857+-1.403/0.8)/7.541
=-1.65

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Elanix Biotechnologies AG  (FRA:ELN) Intrinsic Value: Projected FCF Explanation

The growth multiple is capped between 8.35 and 17.74.

Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.

Elanix Biotechnologies AG's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as

Price-to-Intrinsic-Value-Projected-FCF=Share Price/Intrinsic Value: Projected FCF
=0.053/-1.6494237622502
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Elanix Biotechnologies AG Intrinsic Value: Projected FCF Related Terms

Thank you for viewing the detailed overview of Elanix Biotechnologies AG's Intrinsic Value: Projected FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Elanix Biotechnologies AG (FRA:ELN) Business Description

Traded in Other Exchanges
N/A
Address
Street-4, Georg-Glock, c/o HEUKING KÜHN LÜER WOJTEK, Dusseldorf, NW, DEU, 40474
Elanix Biotechnologies AG is a tissue regeneration company. It develops and commercializes products for acute wound care, dermatological and gynecological applications as well as providing cell technology services. The company's operating segment include Regenerative Medicine and Cosmetic ointments. It generates maximum revenue from the Cosmetic ointments segment. Geographically, it derives a majority of revenue from Switzerland and also has a presence in the EU, and Taiwan.

Elanix Biotechnologies AG (FRA:ELN) Headlines

No Headlines